Every material Form 8-K Vyome Holdings, Inc has filed with the SEC since May 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vyome Holdings appointed Jerry Leonard as Chief Financial Officer on August 27, 2026, with the role taking effect September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, which assigns him to the company. The company will pay ClearbridgeCFO a consulting fee of $15,000 per month, and interim CFO Robert Dickey is resigning effective August 31, 2026, which is a change in the company's finance leadership.
Jerry Leonard appointed CFO by board on August 27, 2026, effective September 1, 2026; he will also serve as principal accounting officer.
Consulting fee of $15,000 per calendar month paid to ClearbridgeCFO, LLC; agreement runs one year and renews automatically for 12-month periods.
Robert Dickey resigns as Interim CFO effective August 31, 2026; the filing says the resignation was not due to any disagreement with the company.
Foresite Advisors, LLC consulting agreement dated August 26, 2024 will be deemed terminated as of August 31, 2026.
Vyome Holdings reported its second-quarter 2026 results, showing a net loss of approximately $720,000, or $0.10 per share, and total operating expenses of approximately $874,000. The company's cash and cash equivalents rose to approximately $7.9 million from $5.0 million at December 31, 2025, but the six-month net loss widened to $1,705,204 from $602,732 a year earlier, and six-month revenue fell to $58,546 from $248,535.
Q2 2026 net loss attributable to common shareholders: approximately $720,000, or $0.10 per basic and diluted share
Cash and cash equivalents: approximately $7.9 million at June 30, 2026, up from $5.0 million at December 31, 2025
Six-month net loss: $1,705,204 in 2026 versus $602,732 in 2025; six-month revenues: $58,546 versus $248,535
Company received the FDA's written response on its VT-1953 clinical development program during the second quarter
Vyome Holdings reported first quarter 2026 results, with revenue of $31,591 compared with $198,581 a year earlier. The company reported a net loss attributable to common shareholders of about $963,000, or $0.15 per share, and cash of $8.8 million at March 31, 2026, up from $5.0 million at December 31, 2025, which the company attributes to a January 2026 share sale.
Q1 2026 revenue was $31,591, down from $198,581 in Q1 2025
Net loss attributable to common shareholders was about $963,000, or $0.15 per share, versus a net loss of $293,974 in Q1 2025
Cash and cash equivalents were about $8.8 million at March 31, 2026, up from about $5.0 million at December 31, 2025
On January 27, 2026, the company raised about $5.29 million by selling 1,089,545 shares at an average of $5.00 per share
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vyome Holdings, Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →